Argenx announces u.s. food and drug administration approval of vyvgart hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis

Vyvgart ® hytrulo is first fda - approved subcutaneous (sc) inject able for generalized myasthenia gravis ( gmg ) with this approval, argenx broadens innovative gmg product offering and demonstrates continued commitment to providing more choice and flexibility for patients e fficacy of vyvgart hytrulo was established by demonstrating a comparable pharmacodynamic (pd) effect to vyvgart ® in phase 3 adapt-sc bridging study management to host conference call tomorrow at 2:30pm cet (8:30 am et) regulated information/inside information amsterdam , the netherlands— june 20 , 2023 —argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the u.s. food and drug administration (fda) approved vyvgart® hytrulo (efgartigimod alfa and hyaluronidase-qvfc). vyvgart hytrulo is an injection for subcutaneous (sc) use for the treatment of generalized myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) antibody positive.
ARGX Ratings Summary
ARGX Quant Ranking